You are currently viewing a new version of our website. To view the old version click .
Cancers
  • Correction
  • Open Access

22 September 2021

Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837

,
,
and
1
Department of Hematology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
2
Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
3
Cancer Center Amsterdam, 1105 AZ Amsterdam, The Netherlands
4
Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, The Netherlands
This article belongs to the Special Issue B Cell Malignancies (including B Cell Lymphoma, Multiple Myeloma and B-CLL)
In the original article [], reference [46] was not cited correctly in Table 1. The citation has now been inserted in Section 2.1. “Immune Checkpoint Blockade”, Table 1: the original citation “Zinzani et al., 2019” should read “Zinzani et al., 2019 [46]”.
In the original article, reference [84] was not cited correctly in Table 3. The citation has now been inserted in Section 2.3. “Chimeric Antigen Receptor Therapy”, Table 3: the original citation “Fraietta et al., 2016 [78]” should read: “Fraietta et al., 2016 [84]”.
The reference citation numbers from Section 3.2. “T-Cell Skewing”, paragraph two, line three onwards were incorrectly written as a result of four missing references in the reference section. They have been corrected after the references were reinserted with the following numbers: [103], [117], [153] and [192]:
103.
Tinhofer, I.; Weiss, L.; Gassner, F.; Rubenzer, G.; Holler, C.; Greil, R. Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J. Immunother. 2009, 32, 302–309, doi:10.1097/CJI.0b013e318197b5e4.
117.
Song, D.G.; Ye, Q.; Carpenito, C.; Poussin, M.; Wang, L.P.; Ji, C.; Figini, M.; June, C.H.; Coukos, G.; Powell, D.J., Jr. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011, 71, 4617–4627, doi:10.1158/0008-5472.CAN-11-0422.
153.
Ramsay, A.G.; Johnson, A.J.; Lee, A.M.; Gorgun, G.; Le Dieu, R.; Blum, W.; Byrd, J.C.; Gribben, J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Investig. 2008, 118, 2427–2437, doi:10.1172/JCI35017.
192.
Ramsay, A.G.; Evans, R.; Kiaii, S.; Svensson, L.; Hogg, N.; Gribben, J.G. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013, 121, 2704–2714, doi:10.1182/blood-2012-08-448332.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.

Reference

  1. van Bruggen, J.A.C.; Martens, A.W.J.; Tonino, S.H.; Kater, A.P. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.